^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    HDAC10 inhibitor

    Related drugs:
    3d
    Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL (clinicaltrials.gov)
    P2, N=22, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> May 2025
    Enrollment open • Trial initiation date
    |
    Epidaza (chidamide) • Columvi (glofitamab-gxbm)
    5d
    Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice. (PubMed, Int J Hematol)
    Between October 2021 and July 2023, 24 patients aged 41 to 88 years (median, 73.4 years) who had undergone prior therapies, including intensive chemotherapy (79.2%) and mogamulizumab immunotherapy (79.2%), received tucidinostat. Treatment-related adverse events were mainly hematologic but were managed over the course of treatment. Our findings indicate that tucidinostat provides survival benefits in patients with relapsed/refractory ATL in clinical practice and highlight key clinical factors for better outcomes.
    Journal
    |
    IL2 (Interleukin 2)
    |
    Epidaza (chidamide) • Poteligeo (mogamulizumab-kpkc)
    6d
    Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P1/2, N=7, Terminated, Great Novel Therapeutics Biotech & Medicals Corporation | N=46 --> 7 | Trial completion date: Jan 2026 --> Jan 2025 | Recruiting --> Terminated; The overall profile does not support development for Hepatocellular Carcinoma
    Enrollment change • Trial completion date • Trial termination
    |
    Stivarga (regorafenib) • Epidaza (chidamide)
    11d
    Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New trial • Real-world evidence
    |
    Avastin (bevacizumab) • Epidaza (chidamide)
    12d
    Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Avastin (bevacizumab) • capecitabine • oxaliplatin • Epidaza (chidamide)
    15d
    Design and Synthesis of Novel Deazapurine DNMT 1 Inhibitors with In Vivo Efficacy in DLBCL. (PubMed, J Med Chem)
    Compound 55 demonstrated good antitumor activity in vivo. Specifically, compound 55 combined with chidamide demonstrated a superior therapeutic effect over the first-line therapy RTX-CHOP in both the DEL and TP53 mutant DLBCL PDX tumor models.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • DNMT1 (DNA methyltransferase 1)
    |
    TP53 mutation
    |
    Epidaza (chidamide)
    18d
    New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cytarabine • azacitidine • Epidaza (chidamide)
    26d
    Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P2, N=33, Recruiting, The First Affiliated Hospital of Xiamen University | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Epidaza (chidamide)
    26d
    A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Epidaza (chidamide)
    26d
    Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma (clinicaltrials.gov)
    P2, N=33, Recruiting, The First Affiliated Hospital of Xiamen University | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Epidaza (chidamide) • Itari (linperlisib)
    27d
    Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Jiao Tong University School of Medicine | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial primary completion date
    |
    RARA (Retinoic Acid Receptor Alpha) • PML (Promyelocytic Leukemia)
    |
    Venclexta (venetoclax) • Epidaza (chidamide)
    1m
    HDAC2-Mediated METTL3 Delactylation Promotes DNA Damage Repair and Chemotherapy Resistance in Triple-Negative Breast Cancer. (PubMed, Adv Sci (Weinh))
    This study not only elucidates the biological function of lactylated METTL3 in tumor cells but also highlights its negative regulatory effect on cisplatin resistance. Additionally, it underscores the nonclassical functional mechanism of Tucidinostat as a HDAC inhibitor for improving the efficacy of cisplatin against TNBC.
    Journal
    |
    WT1 (WT1 Transcription Factor) • HDAC2 (Histone deacetylase 2) • METTL3 (Methyltransferase Like 3)
    |
    cisplatin • Epidaza (chidamide)
    1m
    Chidamide functions as a VISTA/PSGL-1 blocker for cancer immunotherapy. (PubMed, Cancer Immunol Immunother)
    Here, by screening a library of marketed drugs, we identified Chidamide had a strong binding affinity toward VISTA (KD = 5 nM) and blocked VISTA/PSGL-1 under acidic conditions, thereby significantly enhancing the function of CD8+ T cells and inhibiting the tumor growth in immunocompetent murine CT26 tumor model. This study represents the first discovery of Chidamide as VISTA/PSGL-1 blocker for cancer immunotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Epidaza (chidamide)
    1m
    Comprehensive characterization of fatty acid oxidation in triple-negative breast cancer: Focus on biological roles and drug modulation. (PubMed, Eur J Pharmacol)
    Co-treatment with an FAO inhibitor etomoxir enhanced the combined effects of chidamide with established chemotherapy drugs, as well as their efficacy as single agents in TNBC cells. In conclusion, FAO likely exerts pleiotropic biological effects in TNBC and modulating FAO may offer a promising strategy to improve therapeutic outcomes in TNBC.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Epidaza (chidamide) • etomoxir (MIQ-001)
    2ms
    Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the MLL-AF4 gene: a case report and literature review. (PubMed, Front Immunol)
    Following two VCA courses, he received chimeric antigen receptor T-cell therapy, which led to complete metabolic remission and improved prognosis. This case underscores the potential of the VCA regimen as a bridging therapy for EMR in B-ALL with MLL-AF4, although further studies are warranted.
    Review • Journal
    |
    AFF1 (AF4/FMR2 Family Member 1)
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)
    2ms
    A single-arm, exploratory Phase II clinical study of chidamide in combination with anti-PD-(L)1 and tegafur based chemotherapy in second-line treatment of advanced pancreatic cancer (ChiCTR2200058431)
    P2, N=17, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University | N=30 --> 17
    Enrollment change
    |
    Epidaza (chidamide)
    2ms
    Upregulation of CD19 by low-dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma. (PubMed, Discov Oncol)
    In vivo experiments showed that infusion of CD19 CAR T cells after chidamide bridging intervention can enhance the therapeutic effect of B-NHL and prolong the overall survival of mice. This study provides a new direction and theoretical foundation for CD19 CAR T cell therapy in B-NHL.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
    |
    Epidaza (chidamide)
    2ms
    Chidamide in combination with third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced lung adenocarcinoma who have failed third-generation EGFR-TKI therapy: a multicenter exploratory single-arm clinical study (ChiCTR2400094864)
    P=N/A, N=54, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
    New trial
    |
    Epidaza (chidamide)
    2ms
    The efficacy and safety prospective study of Pazopanib in combination with Chidamide and Adebrelimab in unresectable Locally Advanced or Metastatic Renal Cell Carcinoma: a single-centre, single-arm, open-label, phase 2 trial (ChiCTR2500095466)
    P2, N=32, Fudan University Shanghai Cancer Center Urology; Fudan University Shanghai Cancer Center Urology
    New P2 trial
    |
    pazopanib • Epidaza (chidamide) • Ariely (adebrelimab)
    2ms
    A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, Ruijin Hospital
    New trial • Real-world evidence
    |
    Epidaza (chidamide)
    2ms
    CHiR Therapy for Elderly DLBCL Intolerant to Chemo (clinicaltrials.gov)
    P2, N=30, Recruiting, First Affiliated Hospital of Ningbo University
    New P2 trial
    |
    lenalidomide • Brukinsa (zanubrutinib) • Epidaza (chidamide)
    2ms
    Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=45, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P1/2 trial
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    2ms
    Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy (clinicaltrials.gov)
    P2, N=50, Recruiting, First Affiliated Hospital of Ningbo University
    New P2 trial
    |
    Epidaza (chidamide)
    2ms
    Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IFNA1 (Interferon Alpha 1)
    |
    azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)
    3ms
    Clinical Relevance and Drug Modulation of PPAR Signaling Pathway in Triple-Negative Breast Cancer: A Comprehensive Analysis. (PubMed, PPAR Res)
    Lastly, our experimental validation demonstrated the ability of the histone deacetylase (HDAC) inhibitor chidamide to activate the PPAR signal in TNBC cells. In conclusion, the PPAR signaling pathway likely has pleiotropic biological effects in TNBC. These preliminary but interesting findings enhance our understanding of the role played by PPAR signal and provide new insights into the heterogeneity driven by it in TNBC.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency) • PCLO (Piccolo Presynaptic Cytomatrix Protein)
    |
    HRD
    |
    Epidaza (chidamide)
    3ms
    CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • decitabine • Epidaza (chidamide)
    3ms
    A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer (clinicaltrials.gov)
    P2, N=63, Not yet recruiting, Peking University
    New P2 trial • Metastases
    |
    paclitaxel • docetaxel • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • irinotecan • Epidaza (chidamide)
    3ms
    Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) (clinicaltrials.gov)
    P1, N=9, Terminated, Taipei Medical University Shuang Ho Hospital | Trial completion date: Dec 2024 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Mar 2024; The overall profile does not support development for metastatic colorectal cancer
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • RAS mutation • RAS wild-type
    |
    Epidaza (chidamide) • celecoxib oral
    3ms
    Sustained yet non-curative response to lenalidomide in relapsed angioimmunoblastic T-cell lymphoma with acquired chidamide resistance: a case report with 10-year follow-up, genetic insights and literature review. (PubMed, Front Oncol)
    Notably, genes commonly mutated in AITL, including RHOA, TET2, DNMT3A, and IDH2, were absent in this case. A review of the literature highlights the heterogeneous genomic landscape of AITL and the diversity of treatment options available, underscoring the importance of tailored approaches to overcome resistance and improve outcomes in this distinct lymphoma subtype.
    Review • Journal
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • ARID1A (AT-rich interaction domain 1A) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • RHOA (Ras homolog family member A)
    |
    ARID1A mutation • TET2 mutation • KMT2D mutation • Chr del(5q)
    |
    lenalidomide • Epidaza (chidamide)
    3ms
    DEB: Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (clinicaltrials.gov)
    P3, N=423, Active, not recruiting, Chipscreen Biosciences, Ltd. | Trial completion date: Mar 2025 --> Jun 2025
    Trial completion date • Combination therapy
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive • MYC rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
    3ms
    Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Oct 2025 | Trial primary completion date: Sep 2022 --> Aug 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr) • Epidaza (chidamide)
    3ms
    A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients (clinicaltrials.gov)
    P3, N=430, Recruiting, Chipscreen Biosciences, Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • Fruzaqla (fruquintinib) • Epidaza (chidamide)
    4ms
    HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
    New P2 trial • Metastases
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Epidaza (chidamide)
    4ms
    Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL. (PubMed, Ann Hematol)
    In our study, the in vitro and in vivo experiments confirmed that chidamide and venetoclax synergistically inhibited the expression of MYCN and increased the expression of DKK3 by inhibiting the activity of HDAC and BCL2, inhibiting the Wnt/β-catenin signaling pathway and B-ALL cell proliferation. These findings indicate that the HDACi chidamide and the BCL2 inhibitor venetoclax can be used in combination to treat B-ALL, providing a new method and strategy for treating B-ALL.
    Journal • IO biomarker
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • DKK3 (Dickkopf WNT Signaling Pathway Inhibitor 3)
    |
    MYCN expression
    |
    Venclexta (venetoclax) • Epidaza (chidamide)
    4ms
    A Prospective, Open-label Phase II Study of CR-CHOP+X in Previously Untreated DEL (clinicaltrials.gov)
    P2, N=49, Recruiting, Ruijin Hospital
    New P2 trial • IO biomarker
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • decitabine • Epidaza (chidamide) • Inokai (orelabrutinib)
    4ms
    Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia (clinicaltrials.gov)
    P2, N=92, Recruiting, The First Affiliated Hospital of Soochow University | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide)
    4ms
    RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL (clinicaltrials.gov)
    P2, N=44, Recruiting, Zhejiang Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • lenalidomide • cyclophosphamide • epirubicin • Epidaza (chidamide) • vindesine
    4ms
    Sincerely20: Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P2, N=51, Recruiting, Fudan University | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker • Epigenetic controller
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • Epidaza (chidamide)
    4ms
    A Prospective, Open Phase II Clinical Study Evaluating the Safety and Efficacy of chidamide in Combination with Toripalimab and Anlotinib for the Second-Line Treatment of Advanced or Unresectable Soft Tissue Sarcomas (ChiCTR2400090218)
    P2, N=42, Recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P2 trial • Combination therapy • Metastases
    |
    Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi) • Epidaza (chidamide)
    4ms
    Prospective, open-label, phase II clinical study of the combination of Chidamide and Anlotinib ± PD-1/PD-L1 inhibitors in patients with SWI/SNF complex-deficient mutations (ChiCTR2400090522)
    P2, N=57, Recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial • IO biomarker
    |
    ARID1A (AT-rich interaction domain 1A) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    Focus V (anlotinib) • Epidaza (chidamide)
    4ms
    A single-arm, single-center clinical study of chidamide in combination with vinorelbine and capecitabine in the treatment of HER2-negative advanced breast cancer (ChiCTR2400090102)
    P2, N=26, Not yet recruiting, ChongQing university cancer hospital; ChongQing university cancer hospital
    New P2 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • vinorelbine tartrate • Epidaza (chidamide)
    4ms
    Adebrelimab plus Chidamide in combination with Gemcitabine in patients with advanced squamous-cell non-small-cell lung cancer who previously progressed during or after treatment of PD-1 inhibitors (L-Aunching/SCOG-L003): A prospective, single-arm, exploratory trial (ChiCTR2400090083)
    P2, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK fusion
    |
    gemcitabine • Epidaza (chidamide) • Ariely (adebrelimab)